Bloomberg Law
Dec. 8, 2021, 6:33 PM

Third Pfizer-BioNTech Dose Is Key to Fight Omicron’s Spread (1)

Naomi Kresge
Naomi Kresge
Bloomberg News

Pfizer Inc. and BioNTech SE said initial lab studies show a third dose of their Covid-19 vaccine may be needed to neutralize the omicron variant, results that will accelerate booster-shot drives around the world and may lead to use of new strain-specific vaccines.

Company researchers observed a 25-fold reduction in neutralizing antibodies that fight the variant, compared with the original strain of the virus, in people who got just two shots. However, boosting with an additional shot of the vaccine restored protection to a level similar to the initial two-dose regimen, the vaccine partners said in a statement.

LISTEN: Jason Gale, Bloomberg’s Senior Editor, discusses the latest on the omicron variant and vaccines’ impact with Bryan Curtis and Rishaad Salamat on Bloomberg Daybreak Asia.